AB
IKT icon

Amalgamated Bank’s Inhibikase Therapeutics IKT Stock Holding History

Amalgamated Bank’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,900
Closed -$4K – 2197
2025
Q4 		$4K Sell
1,900
-165
-8% -$263 ﹤0.01% 2786
2025
Q3 		$3K Hold
2,065
– – ﹤0.01% 2894
2025
Q2 		$4K Buy
+2,065
New +$4.04K ﹤0.01% 2841

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Amalgamated Bank's IKT Position: Q1 2026 in Review

Amalgamated Bank sold out of Inhibikase Therapeutics (IKT) in Q1 2026, closing a stake of 1,900 shares — an estimated $4K sold.

Amalgamated Bank first reported a position in IKT in Q2 2025 and held it in 3 quarters. The position peaked at $4K in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Amalgamated Bank reported no remaining Inhibikase Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,900 Inhibikase Therapeutics shares in Q1 2026, an estimated $4K.
  • Amalgamated Bank first reported a position in Inhibikase Therapeutics in Q2 2025 and held it in 3 quarters.
  • Amalgamated Bank's Inhibikase Therapeutics position peaked at $4K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.